Goserelin is a hormone regulator, commonly used to treat hormone-dependent diseases such as breast cancer, prostate cancer, endometriosis, etc. Its therapeutic effect is mainly achieved by inhibiting the secretion of sex hormones and reducing the hormone level in the patient's body, so as to inhibit tumor growth or alleviate symptoms. Goserelin can also be used as an adjuvant treatment for some reproductive system-related diseases, such as infertility. This article describes in detail the indications, dosage, side effects, contraindications, and clinical efficacy of Goserelin.
(I) Indications
1. B2-C stage prostate cancer
Goserelin is suitable for combined treatment with flutamide for localized T2b-T4 stage (B2-C stage) prostate cancer. Goserelin and flutamide treatment should be started 8 weeks before the start of radiotherapy and continued during radiotherapy.
2. Prostate cancer
Goserelin is suitable for palliative treatment of advanced prostate cancer.
3. Endometriosis
Goserelin is indicated for the treatment of endometriosis, including pain relief and reduction of endometriotic lesions during treatment. Experience with Goserelin in the treatment of endometriosis is limited to women aged 18 years and older, with treatment for 6 months.
4. Endometrial thinning
Goserelin is used as an endometrial thinner prior to endometrial ablation for dysfunctional uterine bleeding.
5. Advanced breast cancer
Goserelin is indicated for the palliative treatment of advanced breast cancer in premenopausal and perimenopausal women. Estrogen and progesterone receptor values may help predict whether Goserelin treatment may be beneficial. The automatic safety feature of the syringe helps prevent needlestick injuries.
(II) Recommended dose
The recommended dose of Goserelin is 3.6 mg, which should be administered subcutaneously to the anterior abdominal wall below the umbilicus line every 28 days under the supervision of a physician using aseptic technique. Although delays of a few days are allowed, every effort should be made to adhere to the 28-day schedule.
(III) Applicable population
Adults. Pregnant and lactating women, children and elderly patients should use the drug under the guidance of a doctor.
(IV) Contraindications
Goserelin is contraindicated in patients who are allergic to GnRH, GnRH agonist analogs or any component of Goserelin and in pregnant patients.
(V) Side effects
The most common clinically significant adverse reactions occurred in >10% of men: hot flashes, sexual dysfunction, decreased erectile function and lower urinary tract symptoms.
The adverse events in women treated for breast cancer, dysfunctional uterine bleeding or endometriosis were similar, including (>20%): hot flashes, headaches, sweating, acne, mood swings, depression, decreased libido, vaginitis, breast atrophy, seborrheic dermatitis and peripheral edema. Tumor flares can occur when both men and women receiving cancer treatment start using Goserelin.
(VI) Precautions
1. Women of childbearing potential and during pregnancy
2. Tumor flare phenomenon
3. Hyperglycemia and diabetes
4. Cardiovascular disease
5. Hypercalcemia
6. Hypersensitivity reaction
7. Cervical resistance
8. Effect on QT/QTc interval
9. Injection site injury
10. Clinical depression
(VII) Drug interactions
No formal drug-drug interaction studies have been conducted. There are no confirmed interactions reported between Goserelin and other drugs.
(VIII) Storage conditions
Store at room temperature (not exceeding 25°C).
[Warm Tips]: The instructions for some products are frequently changed. Please refer to the actual product.
